Arne Skerra | Professor
TU Munich

Dr. Arne Skerra is Full Professor at the Technical University of Munich in the School of Life Sciences. He started his scientific career in the field of protein engineering, where he pioneered the biosynthesis of functional antibody fragments in E. coli. Apart from several other contributions to this area, including the development of Anticalin® proteins as an alternative to antibodies and the Strep-tag® technology for recombinant protein purification, he invented PASylation® technology to extend the in vivo half-life of therapeutic proteins and peptides. Dr. Skerra is co-founder and Chairman of XL-protein GmbH, a German biotech company that commercially exploits PASylation® technology and develops PASylated biological drug candidates, including antibodies and their fragments, for clinical application.